Jan-18-22 Upgrade Stifel
Hold → Buy
$480
Jan-11-22 Upgrade Barclays
Underweight → Equal Weight
Jan-07-22 Upgrade BofA Securities
Underperform → Neutral
Jan-06-22 Resumed Piper Sandler
Overweight
$450
Jan-06-22 Resumed Morgan Stanley
Equal-Weight
$425
Oct-15-21 Resumed Cowen
Outperform
$550
Aug-19-21 Downgrade SVB Leerink
Outperform → Mkt Perform
$425
Jun-01-21 Upgrade Evercore ISI
Underperform → In-line
$400
Mar-31-21 Upgrade Canaccord Genuity
Hold → Buy
$445
Mar-31-21 Downgrade Atlantic Equities
Overweight → Neutral
$390
Mar-03-21 Initiated Barclays
Underweight
$325
Dec-22-20 Upgrade Piper Sandler
Neutral → Overweight
$340 → $415
Dec-17-20 Upgrade BTIG Research
Neutral → Buy
$410
Oct-13-20 Downgrade Guggenheim
Buy → Neutral
Sep-30-20 Initiated Atlantic Equities
Overweight
$355
Sep-29-20 Downgrade Wolfe Research
Outperform → Peer Perform
Sep-22-20 Downgrade UBS
Buy → Neutral
$390 → $285
Sep-22-20 Downgrade Stifel
Buy → Hold
$380 → $280
Sep-21-20 Upgrade Guggenheim
Neutral → Buy
$345
Sep-21-20 Downgrade JP Morgan
Overweight → Neutral
$390 → $280
Jan-22-22 08:58AM Jan-21-22 05:38PM 09:38AM Jan-20-22 09:38PM 05:38PM 04:05PM 09:00AM Jan-19-22 05:38PM 05:38PM 05:38PM 09:38AM 09:38AM 09:00AM Jan-18-22 09:00AM Jan-17-22 09:04AM Jan-14-22 08:32AM Jan-13-22 12:10PM 09:00AM Jan-12-22 01:00PM 09:35AM 09:31AM Jan-11-22 06:34PM 03:30PM 03:16PM Investor's Business Daily
01:24PM 11:55AM 11:32AM 02:51AM Jan-10-22 04:21PM 04:19PM 04:19PM 04:17PM 04:15PM 04:15PM 08:45AM 08:15AM Jan-07-22 09:30AM 09:01AM Jan-06-22 12:32PM Jan-05-22 05:38PM 04:15PM 09:02AM 07:59AM Jan-04-22 09:00AM Jan-03-22 06:04AM Dec-28-21 09:11AM Dec-27-21 09:18AM Dec-23-21 04:05PM Dec-22-21 12:03PM Dec-20-21 09:02AM 07:05AM Dec-17-21 09:04AM 09:02AM Dec-16-21 05:38PM 06:02AM 05:54AM Dec-15-21 01:06PM 09:06AM Dec-14-21 03:21PM Dec-10-21 12:01PM Dec-09-21 04:00AM Dec-08-21 02:38PM 01:31PM 10:54AM American City Business Journals
Dec-07-21 04:35PM American City Business Journals +5.06%
Dec-06-21 07:05AM Dec-04-21 08:21AM Dec-03-21 01:16PM Dec-02-21 11:31AM Nov-30-21 12:31PM 09:41AM 09:23AM Nov-28-21 04:02AM Nov-24-21 11:30AM Nov-23-21 08:07AM 07:54AM Nov-22-21 05:37PM American City Business Journals
01:16PM Nov-17-21 04:05PM 09:26AM Nov-16-21 02:44PM 01:06PM 12:16PM 11:15AM Nov-15-21 01:21PM Nov-12-21 12:11PM Nov-08-21 01:38PM Nov-07-21 08:56AM Nov-05-21 04:21PM Investor's Business Daily
02:17PM 11:39AM 07:52AM Nov-04-21 11:02PM 05:45PM 04:05PM 10:43AM 08:31AM Nov-03-21 04:05PM 03:25PM 11:40AM
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has collaboration agreements with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer; LetsGetChecked to track COVID-19 variants in California; and Merck & Co., Inc. to develop and commercialize tests that identify genetic mutations used in the assessment of homologous recombination deficiency. The company was incorporated in 1998 and is headquartered in San Diego, California.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
TOUSI SUSAN H SVP, Chief Commercial Officer Jan 12 Sale 425.00 800 340,000 39,274 Jan 13 04:48 PM TOUSI SUSAN H SVP, Chief Commercial Officer Dec 28 Sale 387.06 100 38,706 40,074 Dec 30 04:10 PM Dadswell Charles SVP & General Counsel Dec 22 Sale 380.29 322 122,453 3,283 Dec 23 05:37 PM TOUSI SUSAN H SVP, Chief Commercial Officer Dec 08 Sale 375.00 100 37,500 40,174 Dec 09 04:32 PM Dadswell Charles SVP, General Counsel Nov 22 Sale 377.86 314 118,648 3,605 Nov 24 04:16 PM Aravanis Alexander SVP, Chief Technology Officer Nov 12 Sale 386.35 361 139,472 4,127 Nov 16 04:52 PM Febbo Phillip G. SVP Chief Medical Officer Nov 08 Sale 406.83 1,000 406,830 3,015 Nov 09 04:59 PM Aravanis Alexander SVP, Chief Technology Officer Nov 02 Sale 412.78 2,926 1,207,801 4,679 Nov 04 06:11 PM TOUSI SUSAN H SVP, Chief Commercial Officer Oct 28 Sale 414.35 100 41,435 41,256 Nov 01 04:33 PM Aravanis Alexander SVP, Chief Technology Officer Oct 26 Sale 423.00 2,926 1,237,698 7,605 Oct 28 05:27 PM Dadswell Charles SVP & General Counsel Oct 22 Sale 411.00 314 129,054 4,658 Oct 26 04:48 PM Aravanis Alexander SVP, Chief Technology Officer Oct 19 Sale 411.82 2,926 1,204,972 10,531 Oct 21 05:50 PM Aravanis Alexander SVP, Chief Technology Officer Oct 12 Sale 409.21 2,926 1,197,350 13,457 Oct 14 06:29 PM TOUSI SUSAN H SVP, Chief Commercial Officer Sep 28 Sale 418.04 100 41,804 41,356 Sep 30 04:04 PM Dadswell Charles SVP & General Counsel Sep 22 Sale 436.69 314 137,121 4,972 Sep 23 04:24 PM TOUSI SUSAN H SVP, Chief Commercial Officer Aug 30 Sale 463.50 300 139,050 41,456 Sep 01 07:15 PM Dadswell Charles SVP & General Counsel Aug 23 Sale 489.10 314 153,577 5,286 Aug 25 04:40 PM TOUSI SUSAN H SVP, Chief Commercial Officer Aug 04 Sale 500.00 1,000 500,000 41,756 Aug 05 04:22 PM Hoyt Aimee L SVP, Chief People Officer Aug 04 Sale 500.00 372 186,000 3,757 Sep 08 07:36 PM TOUSI SUSAN H SVP, Chief Commercial Officer Jul 28 Sale 486.41 300 145,923 42,743 Jul 29 04:34 PM Dadswell Charles SVP & General Counsel Jul 22 Sale 482.23 314 151,420 5,576 Jul 26 04:57 PM Aravanis Alexander SVP, Chief Technology Officer Jul 07 Sale 477.59 539 257,421 4,679 Jul 07 06:26 PM TOUSI SUSAN H SVP, Chief Commercial Officer Jun 28 Sale 478.95 300 143,685 43,043 Jun 30 05:27 PM Hoyt Aimee L SVP, Chief People Officer Jun 24 Sale 475.00 500 237,500 4,111 Sep 08 07:36 PM Dadswell Charles SVP & General Counsel Jun 22 Sale 461.01 314 144,757 5,890 Jun 24 05:41 PM Febbo Phillip G. SVP Chief Medical Officer Jun 11 Sale 447.59 1,000 447,588 4,461 Jun 14 05:50 PM DORSA CAROLINE Director Jun 10 Sale 450.00 1,000 450,000 8,501 Jun 14 05:48 PM Hoyt Aimee L SVP, Chief People Officer Jun 10 Sale 450.00 500 225,000 4,611 Sep 08 07:36 PM Dadswell Charles SVP & General Counsel May 24 Sale 403.04 314 126,555 6,204 May 26 04:50 PM TOUSI SUSAN H SVP, Chief Commercial Officer May 20 Sale 400.00 500 200,000 43,343 May 24 04:43 PM FLATLEY JAY T Director May 18 Sale 379.53 4,000 1,518,120 148,933 May 20 04:51 PM TOUSI SUSAN H SVP Product Development May 05 Sale 381.88 300 114,564 43,843 May 06 05:26 PM FLATLEY JAY T Director May 04 Sale 384.15 4,000 1,536,600 152,933 May 06 05:21 PM Dadswell Charles SVP & General Counsel Apr 22 Sale 402.02 314 126,234 6,518 Apr 26 07:52 PM FLATLEY JAY T Director Apr 20 Sale 401.83 4,000 1,607,320 156,933 Apr 22 05:05 PM Hoyt Aimee L SVP, Chief People Officer Apr 06 Sale 424.22 1,000 424,218 5,111 Sep 08 07:36 PM FLATLEY JAY T Director Apr 06 Sale 423.44 4,000 1,693,740 160,933 Apr 07 04:41 PM TOUSI SUSAN H SVP Product Development Apr 06 Sale 423.44 500 211,718 44,143 Apr 07 04:34 PM TOUSI SUSAN H SVP Product Development Apr 05 Sale 386.03 300 115,809 44,643 Apr 07 04:34 PM Hoyt Aimee L SVP, Chief People Officer Apr 05 Sale 386.03 1,000 386,030 6,111 Sep 08 07:36 PM Dadswell Charles SVP & General Counsel Mar 22 Sale 416.24 314 130,699 6,832 Mar 24 04:41 PM FLATLEY JAY T Director Mar 16 Sale 421.06 4,000 1,684,240 164,933 Mar 18 07:20 PM TOUSI SUSAN H SVP Product Development Mar 05 Sale 402.24 800 321,792 44,943 Mar 09 05:29 PM FLATLEY JAY T Director Mar 02 Sale 444.61 4,000 1,778,440 168,933 Mar 04 05:04 PM MCGINNIS KAREN K VP, Chief Accounting Officer Feb 18 Sale 486.75 666 324,176 1,538 Feb 22 05:11 PM TOUSI SUSAN H SVP Product Development Feb 17 Option Exercise 0.00 6,306 0 48,921 Feb 18 04:52 PM SAMAD SAM SVP and CFO Feb 17 Option Exercise 0.00 4,379 0 9,355 Feb 18 04:51 PM RAGUSA ROBERT P SVP, Global Quality & Ops Feb 17 Option Exercise 0.00 6,306 0 12,795 Feb 18 04:49 PM MCGINNIS KAREN K VP, Chief Accounting Officer Feb 17 Option Exercise 0.00 935 0 2,576 Feb 18 04:47 PM Hoyt Aimee L SVP, Chief People Officer Feb 17 Option Exercise 0.00 4,625 0 8,873 Feb 18 04:45 PM Febbo Phillip G. SVP Chief Medical Officer Feb 17 Option Exercise 0.00 3,173 0 7,046 Feb 18 04:44 PM deSouza Francis A President and CEO Feb 17 Option Exercise 0.00 24,521 0 85,934 Feb 18 04:42 PM Dadswell Charles SVP & General Counsel Feb 17 Option Exercise 0.00 3,503 0 8,781 Feb 18 04:41 PM FLATLEY JAY T Director Feb 16 Sale 495.09 500 247,543 3,500 Feb 18 07:08 PM FLATLEY JAY T Director Feb 16 Sale 505.26 4,000 2,021,040 172,933 Feb 18 07:08 PM TOUSI SUSAN H SVP Product Development Feb 05 Sale 431.90 800 345,520 39,713 Feb 09 04:48 PM Hoyt Aimee L SVP, Chief People Officer Feb 02 Sale 444.84 57 25,356 2,359 Feb 03 05:00 PM FLATLEY JAY T Director Feb 02 Sale 444.84 4,000 1,779,360 176,933 Feb 03 04:58 PM MCGINNIS KAREN K VP, Chief Accounting Officer Feb 02 Sale 444.84 72 32,028 1,538 Feb 03 04:57 PM deSouza Francis A President and CEO Feb 01 Sale 439.78 3,000 1,319,330 52,603 Feb 03 04:56 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
